COMPANY

Ollin Biosciences

Profile checked Oct 10, 2026

Keywords: Diabetic Macular Edema Wet Age Related Macular Degeneration Neovascular (Wet) Age-Related Macular Degeneration OLN324

Timeline

Oct 15, 2026 Trial start 3: Phase 3 Study of Intravitreal OLN324 in Adults With Diabetic Macular Edema (DME) (OLN324-CP-03) source ↗
Oct 15, 2026 Trial start 3: Phase 3 Study of Intravitreal OLN324 in Adults With Diabetic Macular Edema (DME) (OLN324-CP-02) source ↗
Oct 15, 2026 Trial start 3: Phase 3 Study of Intravitreal OLN324 in Adults With Neovascular (Wet) Age-related Macular Degeneration (nAMD) (OLN324-CP-04) source ↗
Oct 15, 2026 Trial start 3: Phase 3 Study of Intravitreal OLN324 in Adults With Neovascular (Wet) Age-related Macular Degeneration (nAMD) (OLN324-CP-05) source ↗
Jun 24, 2026 Raise Private equity round — Series B: $330M (total, as published), announced Jun 24, 2026. Source: company's own press page. source ↗ · Form D filed Jun 24, 2026 SEC Form D ↗
Feb 12, 2025 Trial start 1: A Phase 1b Study to Assess the Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy of Intravitreal OLN324 source ↗

Dec 15, 2028 (ESTIMATED) · 3 · Phase 3 Study of Intravitreal OLN324 in Adults With Diabetic Macular Edema (DME) (OLN324-CP-03) · NCT07842016
Dec 15, 2028 (ESTIMATED) · 3 · Phase 3 Study of Intravitreal OLN324 in Adults With Diabetic Macular Edema (DME) (OLN324-CP-02) · NCT07841899
Dec 15, 2028 (ESTIMATED) · 3 · Phase 3 Study of Intravitreal OLN324 in Adults With Neovascular (Wet) Age-related Macular Degeneration (nAMD) (OLN324-CP-04) · NCT07816315
Dec 15, 2028 (ESTIMATED) · 3 · Phase 3 Study of Intravitreal OLN324 in Adults With Neovascular (Wet) Age-related Macular Degeneration (nAMD) (OLN324-CP-05) · NCT07816289

Estimated primary completion per ClinicalTrials.gov. Dates move.

Raised: $330.0M. Last 2 years.

Jun 24, 2026 Private equity round — Series B: $330M (total, as published), announced Jun 24, 2026. Source: company's own press page. source ↗ · Form D filed Jun 24, 2026 SEC Form D ↗

Record	Title	Phase	Status	Start	Primary completion
NCT07842016	Phase 3 Study of Intravitreal OLN324 in Adults With Diabetic Macular Edema (DME) (OLN324-CP-03)	3	Not yet recruiting	Oct 15, 2026	Dec 15, 2028 (estimated)
NCT07841899	Phase 3 Study of Intravitreal OLN324 in Adults With Diabetic Macular Edema (DME) (OLN324-CP-02)	3	Not yet recruiting	Oct 15, 2026	Dec 15, 2028 (estimated)
NCT07816315	Phase 3 Study of Intravitreal OLN324 in Adults With Neovascular (Wet) Age-related Macular Degeneration (nAMD) (OLN324-CP-04)	3	Not yet recruiting	Oct 15, 2026	Dec 15, 2028 (estimated)
NCT07816289	Phase 3 Study of Intravitreal OLN324 in Adults With Neovascular (Wet) Age-related Macular Degeneration (nAMD) (OLN324-CP-05)	3	Not yet recruiting	Oct 15, 2026	Dec 15, 2028 (estimated)
NCT07484074	A Phase 1b Study to Assess the Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy of Intravitreal OLN324	1	Completed	Feb 12, 2025	Oct 10, 2025 (actual)